Overvaluation Warnings for DaVita and Nordson Amid Surge in Insider Selling

Key Facts

1DaVita Inc. shares are considered 14.6% overvalued with $200.1 million in insider selling recorded over the last three months.

2Nordson Corp shares declined 4.0% to $278.57, remaining above the GF Value estimate of $269.36.

As investors scrutinize the sustainability of mid-cap equity gains, financial reports indicate that DaVita Inc. and Nordson Corp. are currently trading above their estimated intrinsic values. According to reports, DaVita shares are considered 14.6% overvalued, a signal reinforced by $200.1 million in insider selling recorded over the last three months. Meanwhile, Nordson shares recently declined 4.0% to close at $278.57, yet they remain notably above the GF Value estimate of $269.36.

These elevated valuations emerge as price-to-earnings ratios for both companies exceed their 5-year medians, prompting analyst caution regarding near-term upside. Comparing sector peers, Fresenius Medical Care (FMS) trades at a lower P/E multiple than DaVita, per market data. The heavy insider liquidation at DaVita, reaching significant volumes recently, suggests a lack of confidence among corporate insiders in maintaining current price levels amid shifting sector dynamics and operational cost pressures.

Traders should watch key technical levels as DVA closed at $208.66 and NDSN at $288.21 (close June 12, 2026). Looking ahead, market sentiment in the industrial sector may be influenced by upcoming Eurozone Industrial Production data, which could impact demand forecasts for Nordson. For DVA, the $204.06 level remains a critical support to monitor, representing the low reached during the June 12 session.